AvenCell
Biotechnology ResearchMassachusetts, United States51-200 Employees
Based on our deep science and focused on patients in need, we develop next generation immunotherapies for hard-to-treat cancers.
Cutting-edge Therapy AvenCell develops next-generation immunotherapies for hard-to-treat cancers, such as the novel allogeneic CD123-directed switchable CAR-T investigational therapy. This innovative approach positions the company as a leader in the field, offering a compelling solution for patients in need of advanced treatment options.
Recent Expansions Recent announcements of EMA approval for Clinical Trial Applications and the launch of updated safety and efficacy data indicate significant progress and expansion within AvenCell. These milestones signal growth opportunities for partnerships, collaborations, and further market penetration in the biotechnology research sector.
Key Personnel Addition The appointment of Maniar as the Chief Medical Officer brings valuable expertise and leadership to AvenCell. With a strong figure heading the medical team, the company is poised to strengthen its research capabilities, explore new avenues for therapies, and potentially attract more interest from investors and collaborators.
Financial Health AvenCell's revenue ranging from $10M to $50M positions it as a financially stable player in the biotechnology research industry. This financial health not only instills trust in potential partners and investors but also indicates a capacity for sustained growth and scalability in operations.
Market Positioning Among similar companies like Genetech Solutions and HealthCell, AvenCell's focus on cutting-edge therapies, recent expansions, key personnel appointments, and solid financial standing sets it apart. Leveraging these strengths can help position AvenCell as a top choice for strategic collaborations, licensing deals, and investments within the competitive landscape.
AvenCell uses 8 technology products and services including Font Awesome, Google Cloud, Stimulus, and more. Explore AvenCell's tech stack below.
AvenCell Email Formats | Percentage |
First.Last@avencell.com | 48% |
Fir.Last@avencell.com | 3% |
FirstL@avencell.com | 1% |
First.Last@avencell.com | 48% |
Biotechnology ResearchMassachusetts, United States51-200 Employees
Based on our deep science and focused on patients in need, we develop next generation immunotherapies for hard-to-treat cancers.
AvenCell's revenue is in the range of $10M$50M
AvenCell's revenue is in the range of $10M$50M